U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07290855) titled 'A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema' on March 12.
Brief Summary: This is a phase IV clinical study. The investigators collect patients with a diagnosis of bradykinin induced angioedema. For a specific study period and prospectively arrange, the eligible patients who has an acute attack of angioedema could be treated by icatibant Injection (Icanticure(R)).
The drug, icatibant injection has been reimbursed by National Health Insurance Agency, Taiwan (NHI) in the treatment of diagnosed patients with hereditary angioedema. However, the reimbursement is still limited fo...